<DOC>
	<DOCNO>NCT00506168</DOCNO>
	<brief_summary>This study evaluate efficacy safety combination chemotherapy irinotecan capecitabine previously untreated metastatic colorectal cancer .</brief_summary>
	<brief_title>Study Irinotecan &amp; Capecitabine Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This single center , single arm , open-label , phase II study evaluate efficacy safety combination chemotherapy irinotecan capecitabine previously untreated metastatic colorectal cancer . Patients young 65 treat irinotecan 100 mg/m2 day 1 8 capecitabine 1,000mg/m2 twice daily day 1 14 every 3 weeks.For patiens equal old 65 , dos irinotecan capecitabine reduce 60 mg/m2 750 mg/2 , respectively . Response assessment perform every 3 cycle chemotherapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm metastatic colorectal cancer ECOG performance status 02 Mesurable lesion No prior chemotherapyk radiotherapy metastatic disease . Prior radiotherapy permit administered target lesion select study provide complete least 4 week registration Adjuvnat chemo radiotherapy complete least 6 month prior start study treatment Adequate organ function Expected survival long 6 month Informed consent Prior systemic chemotherapy metastatic disease Prior treatment oxaliplatin irinotecan CNS metastasis Uncontrolled severe cardiovascular disease Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy Other malignancy within past 3 year except cure nonmelanomatous skin cancer carcinoma situ cervix Psychiatric disorder uncontrolled seizure would preclude compliance Pregnant , nurse woman patient reproductive potential without contraception Patients receive concomitant treatment drug interact capecitabine flucytosine , phenytoin , warfarin et al . Prior unanticipated severe reaction fluoropyrimidine therapy , know dihydropyrimidine dehydrogenase ( DPD ) deficiency Major surgery within 3 week prior study treatment start , lack complete recovery effect major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Colorectal neoplasm</keyword>
	<keyword>Secondary</keyword>
	<keyword>Drug therapy , combination</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Capecitabine</keyword>
</DOC>